Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1574-1578, 2023.
Artigo
em Chinês
| WPRIM
| ID: wpr-1010008
ABSTRACT
Daratumumab is the first CD38 monoclonal antibody drug approved for the treatment of patients with multiple myeloma. It can bind to CD38 expressed by tumor cells, inhibit tumor cell growth and induce myeloma cell apoptosis through a variety of immune-related mechanisms. Meanwhile, CD38 is also expressed in other cells, including regulatory T cells, regulatory B cells and myeloid-derived suppressor cells, which provides a theoretical basis for the treatment of hematological tumor diseases other than non-multiple myeloma diseases. This article reviews the research progress and application of this part.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Hematológicas
/
ADP-Ribosil Ciclase 1
/
Anticorpos Monoclonais
/
Mieloma Múltiplo
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS